AROC vs EQNR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AROC's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. Despite strong profitability metrics and robust earnings growth, elevated debt levels and weak technical momentum weigh on overall health. The stock trades above the Graham Number of $16.59 but below the growth-based intrinsic value of $44.55, suggesting a fair valuation given growth expectations. Analysts are bullish with a $31.56 target, though insider selling and a low technical trend score introduce caution.
Equinor exhibits a stable financial foundation with a Piotroski F-Score of 6/9, but it is currently trading at a severe premium to its deterministic value. The current price of $37.94 is more than double the Graham Number ($18.78) and nearly triple the growth-based intrinsic value ($13.58). This valuation gap is compounded by sharply negative growth metrics, including a 27.3% YoY decline in earnings and a 0/100 bearish technical trend. While the balance sheet is healthier than the sector average, the combination of valuation overshoot and deteriorating fundamentals suggests significant downside risk.
Compare Another Pair
Related Comparisons
AROC vs EQNR: Head-to-Head Comparison
This page compares Archrock, Inc. (AROC) and Equinor ASA (EQNR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.